STOCKHOLM, May 18. 2018 /PRNewswire/ -- This week, dosing was completed according to plan in the second clinical study with Immunose™ FLU, developed with the aim to become a modern and effective nasal influenza vaccine.
- In the perspective of this year's severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer.
-The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without loosing sight of our vision, to offer the first nasal influenza vaccine for children younger than 2 years, adds Hans Arwidsson, CEO of Eurocine Vaccines.
The strategy behind this present study, and its design, was presented in a previous news release dated February 7th, 2018 and can be read at;
The progress of the study can also be followed at; https://clinicaltrials.gov
Results are expected second half of 2018.
CONTACT:
Hans Arwidsson,
Ph.D., MBA
CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com
+46-70-634-0171
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
